1. Home
  2. AIRI vs MEIP Comparison

AIRI vs MEIP Comparison

Compare AIRI & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIRI
  • MEIP
  • Stock Information
  • Founded
  • AIRI 1979
  • MEIP 2000
  • Country
  • AIRI United States
  • MEIP United States
  • Employees
  • AIRI N/A
  • MEIP N/A
  • Industry
  • AIRI Military/Government/Technical
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIRI Industrials
  • MEIP Health Care
  • Exchange
  • AIRI Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • AIRI 13.4M
  • MEIP 13.3M
  • IPO Year
  • AIRI N/A
  • MEIP 2003
  • Fundamental
  • Price
  • AIRI $3.44
  • MEIP $2.15
  • Analyst Decision
  • AIRI
  • MEIP Hold
  • Analyst Count
  • AIRI 0
  • MEIP 1
  • Target Price
  • AIRI N/A
  • MEIP N/A
  • AVG Volume (30 Days)
  • AIRI 24.9K
  • MEIP 6.5K
  • Earning Date
  • AIRI 05-15-2025
  • MEIP 05-13-2025
  • Dividend Yield
  • AIRI N/A
  • MEIP N/A
  • EPS Growth
  • AIRI N/A
  • MEIP N/A
  • EPS
  • AIRI N/A
  • MEIP N/A
  • Revenue
  • AIRI $53,182,000.00
  • MEIP N/A
  • Revenue This Year
  • AIRI $5.59
  • MEIP N/A
  • Revenue Next Year
  • AIRI $5.00
  • MEIP N/A
  • P/E Ratio
  • AIRI N/A
  • MEIP N/A
  • Revenue Growth
  • AIRI 0.29
  • MEIP 33.76
  • 52 Week Low
  • AIRI $3.00
  • MEIP $1.46
  • 52 Week High
  • AIRI $9.44
  • MEIP $4.10
  • Technical
  • Relative Strength Index (RSI)
  • AIRI 48.58
  • MEIP 50.95
  • Support Level
  • AIRI $3.38
  • MEIP $2.05
  • Resistance Level
  • AIRI $3.51
  • MEIP $2.25
  • Average True Range (ATR)
  • AIRI 0.16
  • MEIP 0.11
  • MACD
  • AIRI -0.00
  • MEIP 0.00
  • Stochastic Oscillator
  • AIRI 68.75
  • MEIP 56.52

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: